Aptar Digital Health, a leader in digital health solutions, has announced a partnership with the University of Geneva’s Quality of Life (QoL) technologies lab to advance migraine research. This innovative study seeks to explore the relationship between digital biomarkers from daily activities and migraine episodes, focusing on how lifestyle factors may influence the frequency and severity of migraines. Data for the study will be gathered through Migraine Buddy®, Aptar’s mobile app, which supports a global community of 3.7 million migraine sufferers.
The one-year study will recruit participants to monitor vital signs such as heart rate, sleep patterns, and daily activities like walking and exercise. Participants will also complete quality-of-life and migraine-specific surveys every three months to track their overall condition. The goal is to generate valuable insights into how repetitive daily behaviors impact migraines, with the aim of improving understanding and management of this complex neurological condition.
Migraine affects approximately 12% of the global population, often reducing quality of life and increasing risks of depression, anxiety, and workplace absenteeism. Alexandre Urani, Head of Clinical Product Development at Aptar Digital Health, emphasized the potential impact of this collaboration in providing innovative solutions for managing chronic conditions like migraines.
This partnership highlights the role of digital health in addressing significant public health challenges, offering the potential to improve awareness, research, and treatment options for migraine sufferers worldwide.
Click here to read the original news story.